Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLBWT1)

Drug Name

ALRN-6924 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Haematological malignancy	2B33.Y	Phase 2	[1]
Acute myeloid leukaemia	2A60	Phase 1	[1]
Myelodysplastic syndrome	2A37	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ubiquitin-protein ligase E3 Mdm2 (MDM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7388	DMF5GZI	Acute myeloid leukaemia	2A60	Phase 3	[3]
APG-115	DMIFA0L	Prolymphocytic leukaemia	2A82.1	Phase 2	[1]
AMG 232	DM65PTO	Merkel cell carcinoma	2C34	Phase 2	[4]
ASTX295	DM9EM5G	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
HDM201	DMVRTCW	Haematological malignancy	2B33.Y	Phase 1	[1]
DS-3032	DMA2B5Y	Haematological malignancy	2B33.Y	Phase 1	[6]
RG7775	DMXBS6U	Acute myeloid leukaemia	2A60	Phase 1	[7]
JNJ-26854165	DMNSJ3C	Non-small-cell lung cancer	2C25.Y	Phase 1	[8]
BI 907828	DM2Z4YQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
MI-219	DM196LK	Triple negative breast cancer	2C60-2C65	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting p53-binding protein Mdm4 (MDM4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NSC-207895	DMO5MUY	Solid tumour/cancer	2A00-2F9Z	Preclinical	[11]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
p53-binding protein Mdm4 (MDM4)	TT9OUDQ	MDM4_HUMAN	Inhibitor	[2]
Ubiquitin-protein ligase E3 Mdm2 (MDM2)	TT08GJW	MDM2_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
3	Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015 Apr 30;6(12):10207-21.
4	Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41.
5	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
6	Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36.
7	Phase I clinical trail of RG7775 for treating Acute myelogenous leukemia. Roche.
8	Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741.
9	MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 Nov;34(11):2858-2874.
10	MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26.
11	Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014 Jan;124(1):6-12.